Sirio Pharma Co., Ltd. announced a private placement transaction of not more than 54,051,066 A common shares to be issued for gross proceeds of not more CNY 1,350,000,000 on July 6, 2022. The transaction will include participation from not more than 35 investors. The issue price is not less than 80% of the average price in the 20 trading days before the pricing reference date.

The shares cannot be transferred within 6 months from the issuance closing date. The transaction has been approved in the 10th meeting of the 3rd directorate and the 9th meeting of the 3rd supervisory board, and is subject to the approvals of the company's shareholders and the China Securities Regulatory Commission.